<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712826</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0811</org_study_id>
    <nct_id>NCT03712826</nct_id>
  </id_info>
  <brief_title>Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease</brief_title>
  <acronym>PICTURE</acronym>
  <official_title>Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn disease is an inflammatory chronic disease of the bowel the complex physiopathology of&#xD;
      which brings in immunological, genetic and environmental factors. At present, the appeal to&#xD;
      biotherapics anti-TNFa (infliximab and adalimumab) or anti-IL-12/23 (ustekinumab) in MC&#xD;
      represents a major therapeutic progress at the origin of a significant improvement of the&#xD;
      symptoms, the healing of the intestinal hurts and the quality of life.&#xD;
&#xD;
      Considering the new immunological targets of these biotherapics, the investigators put the&#xD;
      hypothesis that an immunological profile (impulsive person and\or tissular) specific of the&#xD;
      patients with one MC is associated with the answer to biotherapics. So, before beginning the&#xD;
      treatment the patients expressing strongly the pro-inflammatory cytokine TNFa, would more may&#xD;
      be answering machines in anti-TNFa and those with whom the immunological profile is very&#xD;
      marked towards the way Th1/Th17 would more may answer favorably the ustekinumab. The&#xD;
      identification of immunological profiles capable of predicting before treatment the answer&#xD;
      under biotherapics could establish in MC but also in other inflammatory diseases a major step&#xD;
      forward to guide the coverage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>Week 14</time_frame>
    <description>Identify by cytometry of mass a predictive, blood and/or mucous immunological profile, of the answer at week 14 to a biotherapics by anti-TNFa or anti IL-12 / 23 at suffering patients of Crohn disease in relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mass cytometry dosage of immunological markers week 0-week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Measurements of immunological markers by mass cytometry will be performed in the blood at baseline and at week 14 and in the gastrointestinal mucosa (endoscopic biopsies) only at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission at week 14</measure>
    <time_frame>Week 14</time_frame>
    <description>Clinical remission will be defined as a reduction in the CDAI score ≤ 150 at week 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of inflammatory markers</measure>
    <time_frame>week 14</time_frame>
    <description>Assays for inflammatory blood (CRP) and fecal markers (fecal calprotectin) will be performed to predict the response to anti-TNFα or ustekinumab (anti IL-12/23) at inclusion and at week 14, with conventional methods used routinely.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>anti TNF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn patient with antiTNF treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crohn disease with ustekinumab treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-TNF Drug</intervention_name>
    <description>Crohn patient with antiTNF treatment</description>
    <arm_group_label>anti TNF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Crohn disease with ustekinumab treatment</description>
    <arm_group_label>Ustekinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient of more than 18 years old&#xD;
&#xD;
          -  Patient presenting a MC before diagnosed according to the usual criteria&#xD;
&#xD;
          -  Patient in relapse (score CDAI &gt; 150) for at least 1 month&#xD;
&#xD;
          -  requiring Patient a treatment by anti-TNF or ustekinumab according to the indications&#xD;
             of the AMM&#xD;
&#xD;
          -  Patient compatible with the realization of endoscopic digestive biopsies&#xD;
&#xD;
          -  Patient having signed a consent of participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -· patient with Crohn disease with a CDAI score &lt; 150 ·&#xD;
&#xD;
          -  contraindication to anti-TNF and\or ustekinumab ·&#xD;
&#xD;
          -  contraindication to the realization of an iléocoloscopie&#xD;
&#xD;
             ·- Patient taking anti-inflammatory drugs or antibiotics ·&#xD;
&#xD;
          -  Patient presenting complications of the type intestinal sub-occlusion, fistulas or&#xD;
             abdominal abscesses ·&#xD;
&#xD;
          -  Patient having a exclusive perianal disease or having&#xD;
&#xD;
          -  pregnant Women ·&#xD;
&#xD;
          -  Patients having been the object of a vast intestinal resection ·&#xD;
&#xD;
          -  Patient with an ileostomy or a colostomy ·&#xD;
&#xD;
          -  No consent of the patient ·&#xD;
&#xD;
          -  patient under legal protection ·&#xD;
&#xD;
          -  Subject participating in another research which need a period of exclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Boschetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles Boschetti, MD</last_name>
    <phone>04.78.86.03.02</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.boschetti@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Laure Charlois</last_name>
    <phone>04.78.86.37.67</phone>
    <phone_ext>+33</phone_ext>
    <email>anne-laure.charlois@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles Boschetti, MD</last_name>
      <phone>04.78.86.03.02</phone>
      <phone_ext>+33</phone_ext>
      <email>gilles.boschetti@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Laure Charlois</last_name>
      <phone>04.78.86.37.67</phone>
      <phone_ext>+33</phone_ext>
      <email>anne-laure.charlois@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles Boschetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Nancey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Flourié, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn</keyword>
  <keyword>immunological profile</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>anti-TNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

